PeptiStar Inc., ペプチスター株式会社


CAGE Bio, TAGCyx and PeptiStar announce execution of a license and supply agreement for development and commercialization of TAGX-0003 for the treatment of immunodermatology diseases mediated by the IFN-γ pathway


CAGE Bio Inc. (hereinafter “CAGE Bio”), a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology and TAGCyx Biotechnologies Inc. (hereinafter “TAGCyx”), a biotechnology company developing DNA aptamer drugs based on its proprietary artificial nucleic acid base pair technology, announce execution of a license agreement for development of TAGX-0003, for the targeted treatment of alopecia areata and vitiligo by dermatological application.